VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds

Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
You are here: IndiaNotes

Filter search : Quote Research All

Reports for search string : Guidance

Ahluwalia Contracts Q3FY18: Healthy Show on Higher Margin: Maintain BUY
Ahluwalia Contracts (ACIL) has reported a better-than-expected operating performance in 3QFY18, with its reported EBITDA growing sharply by 32% YoY and 25% QoQ to Rs625mn.
Reliance Securities, 21 Feb 2018
PNC Infratech Q3FY18: Operational performance hit by AD delays, revival to be slow; maintain Reduce
PNC Infratech’s (PNCL) 3QFY18 revenues were impacted by delays in receiving AD for projects owing to land acquisition issues. Our thesis of FY18E execution being hit due to slow-moving projects has pl...
Equirus Securities, 20 Feb 2018
Sun Pharmaceuticals Q3 Results: Underlying business resilient; upgrade to ADD
Sun Pharma’s (SUNP) 3QFY18 sales declined 16% yoy to Rs 66.5bn, 6% below EE largely owing to lower growth in domestic and emerging markets. EBITDA/PAT came in 5%/62% below EE.
Equirus Securities, 20 Feb 2018
KNR Constructions Q3FY18: Healthy Performance Continues; Reiterate BUY
We expect KNRC’s revenue and PAT to register 19% and 17% CAGR, respectively through FY17-FY20E on the back of decent order book, healthy margin and expected healthy order inflow in coming months. We r...
Reliance Securities, 20 Feb 2018
Equitas Holdings Q3FY18: MFI stress well provided, opex growth stabilizing
We thus upgrade EQUITAS to ADD with a revised Mar’19 TP of Rs 170 (Sep’18 TP of Rs 135 earlier) set at 2.6x/2.3x FY19E/FY20E ABV.
Equirus Securities, 12 Feb 2018
Lupin Q3FY18: Outlook Remains Weak; Maintain Hold
Lupin (LPC) continued to deliver a weak performance in 3QFY18 from all operational metrics. Its revenue, EBITDA and PAT declined by 11.3% YoY, 43.5% YoY and 65% YoY to Rs39.7bn, Rs6.9bn, Rs2.2bn, resp...
Reliance Securities, 09 Feb 2018
CCL Products India Q3FY18: Good prospects ahead; HOLD
CCL Products (India) Ltd. (CCL) declared its Q3FY18 results recently. Consolidated net revenues decreased by 5.2% to Rs274 crs due to high base in Q3FY17.
Way2wealth, 07 Feb 2018
ICICI Bank Q3FY18: Weak Operational Peformance; HOLD
ICICI Bank continued to surprise negatively on core operating and credit cost front in 3QFY18. Its operating profit dipped by 8.4% YoY and 27.6% % QoQ to Rs50.6bn led by lower other income and a muted...
Reliance Securities, 06 Feb 2018
Supreme Industries Q3FY18: Strong volume growth offset by weak margins; reiterate SHORT
Supreme Industries (SIL) posted an in-line operating performance for 3QFY18 with 19%/15% yoy growth in volume/revenues driven by the pipe and industrial segments.
Equirus Securities, 05 Feb 2018
Alembic Pharmaceuticals Q3FY18:US biz surprises; assign REDUCE
Alembic Pharma’s (ALPM) 3QFY18 sales/EBITDA/earnings grew 9%/29%/51% to Rs 8.4bn/ Rs 1.87bn/Rs 1.31bn, 8%/6%/9% ahead of EE led by higher sales in the US business and API segment.
Equirus Securities, 05 Feb 2018
Karur Vysya Bank Q3FY18: Asset quality to remain under pressure; retain ADD
Strong commission income (+37% yoy) and contained opex (+3.6% yoy) led to an above-expected PAT of Rs 715mn (-38% yoy) for Karur Vysya Bank (KVB) in 3QFY18. Slippages remained elevated.
Equirus Securities, 05 Feb 2018
Ajanta Pharma Q3FY18: Well established to expand its presence; Hold
Ajanta Pharma reported a 10% YoY growth in revenues for the quarter driven by ~80% YoY growth in Asian sales to INR 1610 million. The US sales saw a growth of ~20% YoY during the quarter to INR 710 mi...
SPA Securities, 01 Feb 2018
Shriram Transport Finance: Well-poised for profitable growth; Maintain buy
Shriram Transport Finance Company (STFC) has consistently been showing improvement on major operating front led by higher disbursement and higher operating profit. Its disbursement grew by 64.7% YoY a...
Reliance Securities, 31 Jan 2018
Dr. Reddy’s third quarter marked by one-offs, US pipeline promising – assign ADD
Dr. Reddy’s (DRRD) 3QFY18 operating profits (16% above EE) were influenced by multiple one-offs, adjusting for which EBITDA came in 2% higher than our estimate.
Equirus Securities, 31 Jan 2018
Positional Call: Buy Karnataka Bank for an upside potential of 23%
Company has successfully surpassed landmark achievement of Rs102182 crore business turnover in Q3 by posting a healthy CD ratio of 76.87%. Bank has envisioned a holistic growth by cashing in on goodwi...
Rudra Shares and Stock Brokers, 30 Jan 2018
Dr. Reddy's Lab Q3FY18: PAT in line with estimates; Accumulate
We have rolled forward our earnings to FY20E and derive our TP on 20x of FY20E EPS. With better visibility and outlook, we are revising and upgrading our recommendation to ‘Accumulate’ and increased T...
Prabhudas Lilladher, 30 Jan 2018
Can Fin Homes Q3FY18: Disbursements remain weak, FY18 loan growth guidance lowered; retain REDUCE
CanFin Homes (CANF) 3QFY18 results vindicate our concerns, yet again, on a moderation in the company’s loan growth and pressure on NIMs. We cut our target multiple and retain REDUCE on the stock with...
Equirus Securities, 27 Jan 2018
HCL Tech Q3FY18: IMS softness less comforting; retain ADD
IMS softness continues to be worrying as it grew lower than company average for the third consecutive quarter, while yoy growth (5%) was at its historical low. We modestly adjust our estimates to acco...
Equirus Securities, 27 Jan 2018
Wipro Q3FY18: But for valuations; Retain REDUCE
4Q growth guidance (1-3%) represents yoy growth of 4-6.1% and would be led by (1) traction in BFS, and (2) momentum in the digital business, which contributed 25% to overall revenue and grew 4% qoq.
Equirus Securities, 25 Jan 2018
Cyient Q3FY18: Better than feared; retain ADD
Cyient Limited (CYL) reported better-than-feared 3QFY18 earnings as services growth (4.2% qoq, US$ terms) outweighed the decline in DLM (-23.2% qoq) business.
Equirus Securities, 23 Jan 2018
View All

Intraday Tips

What are technical calls?
* SEBI certified analyst

View Stock Advice by: